REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a world chief in minimally invasive remedies for lung illness, as we speak introduced that it’ll launch monetary outcomes for the third quarter of 2022 after the shut of buying and selling on Thursday, November 3, 2022. Company administration will host a convention name to talk about monetary outcomes starting at 1:30 p.m. PT / 4:30 p.m. ET.
Participants are required to register on-line, and may achieve this at minimal quarter-hour earlier than the beginning of the decision. Investors fascinated about listening to the convention name are requested to register on-line or view the stay and archived webcast of the occasion out there on the “Investors” part of the Pulmonx web site at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a world chief in minimally invasive remedies for extreme lung illness. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and deal with sufferers with extreme emphysema/COPD who regardless of medical administration are nonetheless profoundly symptomatic. Pulmonx obtained FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially out there in additional than 25 international locations, with over 100,000 valves used to deal with greater than 25,000 sufferers. For extra data on the Zephyr Valves, please go to https://uspatients.pulmonx.com/. For extra data on the corporate, please go to www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered logos of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
buyers@pulmonx.com
